Analytical Data
-
Gene name
SSSCA1
- Application
-
Alternative Names
ZNRD2;SSSCA1;Protein ZNRD2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60232
-
Expression Region
1-199aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMGSMALNGAEVDDFSWEPPTEAETKVLQAR RERQDRISRLMGDYLLRGYRMLGETCADCGTILLQDKQRKIYCVACQELD SDVDKDNPALNAQAALSQAREHQLASASELPLGSRPAPQPPVPRPEHCEG AAAGLKAAQGPPAPAVPPNTDVMACTQTALLQKLTWASAELGSSTSLETS IQLCGLIRACAEALRSLQQLQH
-
Molecular Weight
24 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The SSSCA1 (Slow Skeletal Muscle and Cardiac Isoform 1) protein has gained attention in the field of biomedical research due to its significant role in muscle physiology and potential implications in various muscular disorders. Initially identified in studies focusing on skeletal muscle function, SSSCA1 is believed to be involved in the regulation of muscle contraction and energy metabolism. Abnormalities in SSSCA1 expression have been associated with muscular dystrophies and other myopathies, highlighting its potential as a biomarker for muscle-related diseases. The increasing prevalence of such conditions necessitates a deeper understanding of the molecular mechanisms involving SSSCA1, which can pave the way for novel therapeutic strategies. Recent advancements in recombinant protein technology have enabled researchers to produce SSSCA1 in heterologous systems, facilitating in-depth studies of its structure and function. These studies aim to elucidate the protein's interaction with other muscle proteins, its post-translational modifications, and its role in muscle development and regeneration. Ultimately, characterizing SSSCA1 through recombinant protein research holds promise for advancing our knowledge of muscle biology and developing targeted interventions for muscular disorders.
